期刊文献+

他汀类药物消退动脉粥样斑块机制探讨 被引量:8

下载PDF
导出
摘要 他汀类药物即3-羟基3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂,通过竞争性抑制内源性胆固醇合成限速酶(HMG-CoA还原酶),使细胞内胆固醇合成减少,达到降低胆固醇水平的目的,被认为是治疗高胆固醇血症的首选药物。同时,多项研究已经证实他汀类药物能消退动脉粥样斑块或减慢其进展,但目前这一病理生理过程的详细机制并不清楚。总结了近年来国内外研究成果,分析其机制可能与他汀类药物的调脂、改善血管内皮细胞功能、抑制血管炎症反应、稳定斑块等多种因素有关,为深入研究其确切机制奠定了理论基础。
出处 《中国慢性病预防与控制》 CAS 2007年第5期516-518,共3页 Chinese Journal of Prevention and Control of Chronic Diseases
  • 相关文献

参考文献22

  • 1Maron DJ, Fazio S, Linton MF. Current perspectives on statins[J]. Circulation, 2000, 101: 207-213.
  • 2Yonemura A, Momiyama Y, Fayad ZA, et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging[J]. J Am Coll Cardiol, 2005,45: 733-742.
  • 3Werner N, Nickening G, Laufs U. Pleioropic effects of HMG-CoA reductase inhibitors[J]. Basic Res Cardiol, 2002, 97:105-116.
  • 4Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes[J]. Circulation, 2001, 103: 1955-1960.
  • 5Nissen SE, Murat TEM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease[J]. N Engl J Med, 2005, 352: 29-38.
  • 6肖玉梅,杨景宁,蒙应东.阿托伐他汀和辛伐他汀对降脂及消退颈动脉斑块疗效的对比研究[J].广东医学院学报,2006,24(1):5-7. 被引量:6
  • 7徐军霞,张冬梅,姚俊华,祝梅华.不同剂量阿托伐他汀治疗颈动脉粥样硬化斑块的临床观察[J].中华高血压杂志,2006,14(9):753-754. 被引量:14
  • 8Parhofer KG, Laubach ER. Barrett PH. Effect of atorvastatin on post- prandial lipoprotein metabolism in hypertriglyceridemic patients [J]. J Lipid Res, 2003, 44:1192-1198.
  • 9Burnett JR, Barrett PH, Vicini PD, et al. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance of postprandial triglyceride-rich lipoproteins in miniature pigs[J]. Arterioscler Thromb Vasc Biol, 1998, 18: 1906-1914.
  • 10Kawakami A, Tanaka A, Nakajima K, et al. Atorvastatin attenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions[J]. Circ Res, 2002, 91: 263-271.

二级参考文献25

  • 1杜书章,岳晓红,杨国杰,张晓坚,康建.阿托伐他汀治疗高血压患者动脉粥样硬化[J].医药论坛杂志,2006,27(8):17-18. 被引量:23
  • 2[1]Grundy SM,Clemen JL,Mers CN,et al.Implication of recent clinical trials for the national cholesterol education program adult treatment panel Ⅲ guideline[J].Circulation,2004,110:227-230.
  • 3[3]Roivainen M,Kajander MV,Palosuo P,et al.Infections,Inflammation,and the risk of coronary heart disease[J].Circulation,2000,101:252-259.
  • 4[4]Downs JR,Clearfield M,Whitney E,et al.Primary prevention of acute coronary events with lovastatin in men and women with average choresterol levels[J].JAMA,1998,1615-1622.
  • 5THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP.Randomised trial of cholesterol lowering in 4444 patients with coronary heart diseases:the Scandinvavian Simvastatin Survival Study(4S)[J].Lancet,1994,344(8934):1383-1389.
  • 6LEA A P,McTAVISH D.Atorvastatin,a review of its pharmacology and therapeutic potential in the management of hyperlipidemias[J].Drugs,1997,53(5):828-847.
  • 7SHEPHERD J,COBBE S M,FORD I,et al.Prevent of coronary heart disease with provastatin in men with hypercholesterolemia[J].N Engl J Med,1995,333(20):1301-1307.
  • 8SACKS F M,PFEFFER M A,MOYE L A,et al.The effect of pravestation on coronary events after myocardial infarction in patients with average cholesterol levels[J].N Engl J Med,1996,335(14):1001-1009.
  • 9BLANKENBORN D H,AZEN S P,KRAMSH D M,et al.Coronary angiographic changes with lovastatin therapy,the monitored atherosclerosis regression study (MARS)[J].Ann Intern Med,1993,119(10):969-976.
  • 10OLIVER M F,De FEYTER P J,LUBSEN J,et al.Effects of simavastarin on coronary atheroma:the Multicentre Anti-Aatheroma Study (MAAS)[J].Lancet,1994,344(8924):762.

共引文献22

同被引文献79

引证文献8

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部